HK Stock Market Move | ZAI LAB (09688) rises by over 5%, the latest data on preclinical studies of ZL-1503 is positive.

date
09:45 20/04/2026
avatar
GMT Eight
Zai Ding Medicine (09688) rose more than 5%, up 5.64% as of the time of publication, at 19.3 Hong Kong dollars, with a turnover of 1.2 billion Hong Kong dollars.
ZAI LAB (09688) rose more than 5%, at the time of drafting, it increased by 5.64%, to 19.3 Hong Kong dollars, with a trading volume of 1.2 billion Hong Kong dollars. On the news front, on April 18, ZAI LAB announced the latest data from the preclinical study of ZL-1503, indicating that this IL-13/IL-31R bispecific antibody developed by the company may continue to suppress severe itching and inflammation caused by atopic diseases. The results of the study were presented at the IMMUNOLOGY2026 conference in Boston, Massachusetts, confirming further that ZL-1503 is expected to become a pioneering therapy for moderate to severe atopic dermatitis and other diseases driven by IL-13 and IL-31. It is reported that ZAI LAB initiated the first phase 1/1b clinical study of ZL-1503 in December 2025; clinical data is expected to be released in the second half of 2026.